Review Article
Molecular Alterations of PI3K/Akt/mTOR Pathway: A Therapeutic Target in Endometrial Cancer
Table 2
PI3K/Akt/mTOR inhibitors in ongoing trials.
| | Ongoing trials | Target kinase | Clinical trial phase | | PFS | ClinicalTrials.gov identifier |
| | PF-04691502 + PF-05212384 | PI3K/mTOR | Phase II | Recruiting | | NCT01420081 | | XL147 | PI3K | Phase II | 65 | 6 months | NCT01013324 | | MK2206 | Akt | Phase II | Recruiting | | NCT01307631 | | Temsirolimus + pegylated liposomal Doxorubicin | mTOR | Phase I | Recruiting | | NCT00982631 | | Ridaforolimus or progestin or chemotherapy | mTOR | Phase II | 130 | | NCT00739830 | | Ridaforolimus + paclitaxel + carboplatin | mTOR | Phase I | Recruiting | | NCT01256268 | | Temsirolimus + bevacizumab | mTOR + VEGF | Phase II | Recruiting | | NCT01010126 | | OSI-027 | mTORC1 + mTORC2 | Phase II | 128 | | NCT00698243 |
|
|
: number of patients; PFS: progression free survival.
|
